Meet the Team
Peptest has been developed by UK-based RD Biomed, a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire.
Innovators in healthcare product development, RD Biomed focusses on gastroenterology and develops products that identify, prevent and treat various medical conditions, such as gastroesophageal reflux disease and laryngopharyngeal reflux.
In Peptest, RD Biomed has developed a novel diagnostic test which can rapidly detect the gastric enzyme pepsin in saliva/sputum and exhaled breath condensate samples.
Remembering Professor Peter Dettmar
Professor Peter Dettmar invented and developed Peptest and was the founder of RD Biomed.
He was also the former global Research and Development Director in Gastrointestinals for Reckitt Benckiser Healthcare (UK) Limited.
Peter had extensive experience in running product development programmes and clinical trials and more than 35 years’ experience of the pharmaceutical industry.
Get in touch…
Want to know more about Peptest? Or do you have a question for the team? Please use the contact form below.
Peptest™ is a single use in-vitro diagnostic device not for ingestion. It conforms to the European Directive 98/79/EC on in-vitro Diagnostic Medical Devices; this is shown by the CE mark of conformity.
Peptest™ kits are manufactured in the UK by RDBiomed Limited.
RDBiomed Limited
Castle Hill Hospital
Castle Road
Cottingham
HU16 5JQ, UK
VAT Number: GB 990 1918 96
Follow
